The British journal of radiology · 2026
99mTc-HYNIC-PSMA-11 whole-body SPECT/CT: a clinically viable alternative to 68Ga-PSMA PET/CT in patients with prostate cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hooda Monika, Kaur Komalpreet, Watts Ankit, Singh Harmandeep, Kaur Harneet, Gunasekaran Vinisha, Sharma Aditya P, Mavuduru Ravimohan, Singh Baljinder
Аннотация
OBJECTIVES: The diagnostic performance of 99mTc-HYNIC-PSMA-11 whole-body SPECT/CT versus 68Ga-PSMA PET/CT was evaluated in prostate cancer patients.
METHODS: As a part of the diagnostic workup, all the prostate cancer (PCa) patients (n = 10; mean age 66.4 ± 9.6 years) underwent whole-body 68Ga-PSMA-11 PET/CT followed by serial whole-body (anterior and posterior) 99mTc-HYNIC-PSMA-11 imaging The serial whole-body imaging was performed at multiple time points of 10 minutes, 2 hours, 4 hours, 6 hours, 24 hours and the whole-body SPECT/CT was acquired at 3 hours. The whole-body SPECT/CT data was analysed for lesions detection and to calculate the standardized uptake values (SUVmax) for 99mTc-HYNIC-PSMA-11 avid lesions using the Q-Metrix software. These values were compared with the corresponding SUVmax values obtained from 68Ga-PSMA-11 PET/CT. The serial whole-body imaging data were used for estimating the radiation absorbed doses (mSv/MBq) to various organs using the MIRD schema and the OLINDA/EXM software.
RESULTS: 68Ga-PSMA-11 PET/CT identified a total of 64 metastatic lesions, while 99mTc-HYNIC-PSMA-11 SPECT/CT detected 49/64 metastatic lesions, presenting a sensitivity of 76.6%. Notably, the mean SUVmax values for 68Ga-PSMA-11 PET/CT and 99mTc-HYNIC-PSMA-11 were comparable and a highly significant positive correlation (r > 0.93; P < .01) The average absorbed doses to the salivary glands, lungs, kidneys, urinary bladder, and liver were found to be comparable with 99mTc-MDP bone scanning.
CONCLUSIONS: The diagnostic performance of whole-body 99mTc-HYNIC PSMA-11 SPECT/CT is fairly comparable to 68Ga-PSMA PET/CT and offers a favourable dosimetry indicating its potential for PCa evaluation.
ADVANCES IN KNOWLEDGE: 99mTc-PSMA-11 SPECT/CT may be an alternative and cost-effective tool for evaluation of initial PSMA disease burden as well as for response evaluation to PSMA targeted therapies.
METHODS: As a part of the diagnostic workup, all the prostate cancer (PCa) patients (n = 10; mean age 66.4 ± 9.6 years) underwent whole-body 68Ga-PSMA-11 PET/CT followed by serial whole-body (anterior and posterior) 99mTc-HYNIC-PSMA-11 imaging The serial whole-body imaging was performed at multiple time points of 10 minutes, 2 hours, 4 hours, 6 hours, 24 hours and the whole-body SPECT/CT was acquired at 3 hours. The whole-body SPECT/CT data was analysed for lesions detection and to calculate the standardized uptake values (SUVmax) for 99mTc-HYNIC-PSMA-11 avid lesions using the Q-Metrix software. These values were compared with the corresponding SUVmax values obtained from 68Ga-PSMA-11 PET/CT. The serial whole-body imaging data were used for estimating the radiation absorbed doses (mSv/MBq) to various organs using the MIRD schema and the OLINDA/EXM software.
RESULTS: 68Ga-PSMA-11 PET/CT identified a total of 64 metastatic lesions, while 99mTc-HYNIC-PSMA-11 SPECT/CT detected 49/64 metastatic lesions, presenting a sensitivity of 76.6%. Notably, the mean SUVmax values for 68Ga-PSMA-11 PET/CT and 99mTc-HYNIC-PSMA-11 were comparable and a highly significant positive correlation (r > 0.93; P < .01) The average absorbed doses to the salivary glands, lungs, kidneys, urinary bladder, and liver were found to be comparable with 99mTc-MDP bone scanning.
CONCLUSIONS: The diagnostic performance of whole-body 99mTc-HYNIC PSMA-11 SPECT/CT is fairly comparable to 68Ga-PSMA PET/CT and offers a favourable dosimetry indicating its potential for PCa evaluation.
ADVANCES IN KNOWLEDGE: 99mTc-PSMA-11 SPECT/CT may be an alternative and cost-effective tool for evaluation of initial PSMA disease burden as well as for response evaluation to PSMA targeted therapies.
Предметные рубрики MeSH
HumansMaleProstatic NeoplasmsGallium RadioisotopesWhole Body ImagingAgedGallium IsotopesPositron Emission Tomography Computed TomographyRadiopharmaceuticalsEdetic AcidOrganotechnetium CompoundsOligopeptidesMiddle AgedSensitivity and SpecificitySingle Photon Emission Computed Tomography Computed Tomography